Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1613 1646 1655
This examiner grants 66% of resolved cases
Mark V. Stevens serves as a patent examiner in Tech Center 1600 and Art Unit 1600. He has overseen 873 resolved cases. The examiner demonstrates an allowance rate of 65.5 percent, which indicates the proportion of applications that successfully reach issuance. This rate provides a clear expectation for practitioners regarding the probability of a grant when their cases are assigned to this examiner.
The data highlights a significant interview lift of 41.6 percent. This metric suggests that conducting an interview with the examiner is a highly effective strategy for moving a case toward allowance. Practitioners can use this 41.6 percent lift to justify the time and expense of direct communication, as it represents a measurable improvement in the likelihood of a positive outcome. This is a key tactical consideration for Tech Center 1600.
The median time to allowance is 974 days. This duration defines the typical timeframe for the prosecution cycle for successful applications. When managing a portfolio, practitioners can use this 974 day figure to estimate the period required to navigate the examination process. The 873 resolved cases provide a stable basis for these metrics in Art Unit 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18984644 | PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINE | Non-Final OA | ANTECIP BIOVENTURES II LLC |
| 18775416 | POROUS MEDICAL DEVICE AND METHODS OF USE | Non-Final OA | Boston Scientific Scimed, Inc. |
| 18517448 | ANTI-TUMOR AGENT | Non-Final OA | FUJIFILM Corporation |
| 18911341 | ORAL CARE COMPOSITIONS COMPRISING DICARBOXYLIC ACID | Non-Final OA | The Procter & Gamble Company |
| 18572884 | COMPOSITIONS AND METHODS FOR INCREASING THE EFFICACY OF IMMUNOTHERAPIES AND VACCINES | Final Rejection | The Regents of the University of Michigan |
| 18684750 | HERBICIDAL MALONAMIDES | Non-Final OA | BASF SE |
| 18870231 | HERBICIDAL DERIVATIVES | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18802080 | SOLVENT-BASED DETERGENT COMPOSITIONS AND METHODS FOR HYDROPHOBIC SOIL REMOVAL | Non-Final OA | ECOLAB USA INC. |
| 18169695 | HEMOSTATIC NANOPARTICLES FOR THE TREATMENT OF NON-COMPRESSIBLE HEMORRHAGE AND INTERNAL BLEEDING | Final Rejection | The General Hospital Corporation |
| 18738288 | Zinc Phosphate Complex | Final Rejection | Colgate-Palmolive Company |
| 18594760 | Oral Care Compositions and Methods of Use | Final Rejection | Colgate-Palmolive Company |
| 18992397 | BIOLOGICAL CONTROL OF SOFT ROT AND BIOFILMS BY MICROBIAL PREDATORS ENCAPSULATED IN CARRIERS | Non-Final OA | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION |
| 18293204 | POLYMER NANOPARTICLES VIA CONDENSED DROPLET POLYMERIZATION | Final Rejection | CORNELL UNIVERSITY |
| 18677400 | COMPOSITION FOR TREATMENT OF WOUNDS CONTAINING STEM CELL-DERIVED EXOSOMES AND METHOD FOR PREPARING SAME | Final Rejection | BREXOGEN INC. |
| 18847701 | HAIR CONDITIONER FORMULATION | Non-Final OA | Dow Silicones Corporation |
| 18370928 | CANNABIS FARMING SYSTEMS AND METHODS | Final Rejection | INSECTERGY, LLC |
| 18555446 | PEPTIDES, NANOVESICLES, AND USES THEREOF FOR DRUG DELIVERY | Non-Final OA | NATIONAL RESILIENCE, LLC |
| 18273694 | TOPICAL FORMULATION CONTAINING MODIFIED PHOSPHOLIPID COMPOUNDS | Non-Final OA | EGIS GYÓGYSZERGYÁR ZRT. |
| 18257526 | GLYCOSYLATED BACTERIORUBERINS AND INDUSTRIAL APPLICATIONS THEREOF | Non-Final OA | NAOS INSTITUTE OF LIFE SCIENCE |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy